Age-Related Macular Degeneration (AMD) Analysis
Registering a CAGR of 7.6% during the forecast period (2016–2022), the global age-related macular degeneration (AMD) market is projected to garner $8.9 billion by 2022, significantly growing from $5.3 billion in 2015.
The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness.
research analysis report: bit . ly/age-related-macular-degeneration-S
Thank you for sharing your research
. Age-related macular degeneration is certainly on the rise with an estimated 196 million people worldwide affected by AMD in 2020. Hopefully the growing market will also lead to continued growth in the treatment landscape. Thanks so much for commenting! - Shelby, MacularDegeneration.net Team Member 
This is interesting but I wonder what is actually included in the "market"? Is this a financial statistic that reflects drugs, supplements and treatments? Does it also include health-care provider fees? What about services and devices specific to the needs of people lifing with macular degeneration? I'm just curious. Denny, MacularDegeneration.net Forum Moderator.
